Results 1 to 10 of about 4,313 (158)

Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

Journal of Asthma and Allergy, 2018
Pamela L Zeitlin,1 Mila Leong,2 Jeremy Cole,3 Raburn M Mallory,4 Vivian H Shih,5 Richard F Olsson,6 Mitchell Goldman5 On behalf of the ALIZE study investigators 1Department of Pediatrics, National Jewish Health, Denver, CO, USA; 2Pediatric Pulmonary and ...
Zeitlin PL, Leong M, Cole J, Mallory RM, Shih VH, Olsson RF, Goldman M   +6 more
doaj  

Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection

Respirology Case Reports, 2021
Chronic eosinophilic pneumonia (CEP) is a rare disorder characterized by marked accumulation of eosinophils in lung tissues and/or bronchoalveolar lavage fluid (BALF). Patients with CEP usually respond well to corticosteroids.
Tomotsugu Takano, Yuh Inutsuka, Satoshi Nakamura, Nobuhisa Ando, Masashi Komori   +4 more
doaj   +1 more source

Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study

BMC Pulmonary Medicine
Purpose This real-world study compared the efficacy and the proportion of patients attaining the criteria constituting clinical remission at 12 months between mepolizumab and benralizumab in patients with severe eosinophilic asthma.
Wei-Chun Huang, Yi-Luen Shen, Wen-Chien Cheng, Chien-Wen Huang, Chia-Hung Chen, Chih- Yen Tu, Wu-Huei Hsu   +6 more
doaj   +1 more source

Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma

Journal of Asthma and Allergy, 2022
Saad AlShareef,1 Christine F McDonald,2– 4 Joy Lee2,5 1Department of Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317-4233, Saudi Arabia; 2Department of Respiratory and Sleep Medicine, Austin Health ...
AlShareef S, McDonald CF, Lee J
doaj  

Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience

Annals of Medicine
Objectives Benralizumab emerged as a promising treatment option for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the long-term effectiveness and safety of benralizumab in patients with severe asthma and relapsing-refractory ...
Federica Davanzo, Luca Iorio, Marta Codirenzi, Eleonora Fiorin, Gabriella Guarnieri, Alessia Achille, Fulvia Chieco Bianchi, Maria Rita Marchi, Andrea Vianello, Andrea Doria, Roberto Padoan   +10 more
doaj   +1 more source

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis

Medicina, 2019
A 56-year-old man with severe asthma underwent bronchial thermoplasty (BT). However, his asthma exacerbated and hypereosinophilia developed 2 months later, thus necessitating oral corticosteroid (OCS) therapy.
Hiroaki Tsurumaki, Toshiyuki Matsuyama, Kazuma Ezawa, Yasuhiko Koga, Masakiyo Yatomi, Haruka Aoki-Saito, Kazuaki Chikamatsu, Takeshi Hisada   +7 more
doaj   +1 more source

Geographic and economic influences on benralizumab prescribing for severe asthma in Japan

Scientific Reports
Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma.
Nobuaki Kobayashi, Hiromi Matsumoto, Kohei Somekawa, Ayami Kaneko, Nobuhiko Fukuda, Suguru Muraoka, Yukiko Ohtsu, Momo Hirata, Ryo Nagasawa, Sousuke Kubo, Kota Murohashi, Hiroaki Fujii, Ayako Aoki, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Takeshi Kaneko   +16 more
doaj   +1 more source

Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results

Journal of Asthma and Allergy, 2019
Gary T Ferguson,1 Jeremy Cole,2 Magnus Aurivillius,3 Paul Roussel,4 Peter Barker,4 Ubaldo J Martin4 On behalf of the GRECO study investigators1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 2OK Clinical Research, LLC,
Ferguson GT, Cole J, Aurivillius M, Roussel P, Barker P, Martin UJ   +5 more
doaj  

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series

Journal of Asthma and Allergy, 2021
Francesco Menzella,1 Marco Bonavia,2 Matteo Bonini,3 Maria D’Amato,4 Salvatore Lombardo,5 Nicola Murgia,6 Vincenzo Patella,7,8 Massimo Triggiani,9 Girolamo Pelaia10 1Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS,
Menzella F, Bonavia M, Bonini M, D'Amato M, Lombardo S, Murgia N, Patella V, Triggiani M, Pelaia G   +8 more
doaj  

Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use

Therapeutics and Clinical Risk Management, 2018
Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai &ndash ...
Maselli DJ, Rogers L, Peters JI
doaj